Roche subsidiary Ventana Medical Systems will pay $100m for BioImagene on a debt-free basis.

Switzerland-based drugs company Roche has acquired BioImagene, a US-based medical device company backed by corporate venturing groups at industrial conglomerate Siemens and Ascension Health.

Roche subsidiary Ventana Medical Systems will pay $100m for BioImagene on a debt-free basis.

In October 2008, BioImagene raised its series D round for more than $26m from Siemens Venture Capital, merchant bank Burrill & Company, Ascension Health Ventures and venture capital firms Artiman Ventures, ICCP Venture Partners and National Healthcare Services.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?